MOSCOW, April 8 – RIA Novosti. More than 1.2 million doses of the EpiVacCorona vaccine were released in February-March, 600 thousand complete sets of the drug, the production rate is planned to be significantly increased, Rinat Maksyutov, Director General of the State Scientific Center for Virology and Biotechnology Vector of Rospotrebnadzor, said in an interview with RIA Novosti.
“In 2021, in February and March, we jointly produced more than 1 million 200 thousand doses of vaccine, which corresponds to 600 thousand complete kits. With the help of our industrial partners EpiVac, Vector-BiAlgam and Geropharm, we expect to increase the pace of vaccine production and by the summer to reach the production volume of five million doses per month, “Maksyutov said.
He specified that at present the EpiVacCorona vaccine is produced at two sites: in the Vector center and in the Vector-BiAlgam company.
EpiVacCorona is the second (after Sputnik V) vaccine registered in Russia for the prevention of coronavirus. It was developed by the State Scientific Center “Vector”.